MAR 22, 2020 7:48 AM PDT

What is "Shotgun ion mobility mass spectrometry sequencing"?

Research published recently in Nature Communications highlights a new method of mapping an essential family of polysaccharides called GAGs (glycosaminoglycans). GAGs are critical to regulating many biological functions such as inflammation, neurodegeneration and tumor metastasis. One common type of GAG is called heparin and is currently used in clinical settings in an anticoagulant drug. Yet, aside from heparin, to date GAGs have been difficult to understand and only several structures have been accurately mapped.

Now the study from the Danish National Research Foundation Centre for Glycomics at the Department of Cellular and Molecular Medicine, University of Copenhagen, offers new insight on GAG mapping methods.

Photo: Pixabay

"Determining the structures is a key question in the research about sugars. If we know the structure, we can determine what the cues are for specific biological functions and consider potential ways to exploit this in the development of therapeutics. This is hugely important and clinically relevant, as shown by the widely used anti-coagulant heparins, and the potential application of new heparin-based drugs for multiple diseases in the future," says the corresponding author, Dr. Rebecca Louise Miller, who is an Assistant Professor at the Copenhagen Center for Glycomics.

The method that Dr. Miller and her team have developed is called "Shotgun ion mobility mass spectrometry sequencing" or SIMMS2. It’s a complicated name and an even more complicated process akin to breaking sugar structures into small puzzle pieces in order to identify their genetic fingerprints and compare them to know existing structures. Through this process, they are able to sequence larger GAG structures.

"The instrumentation behind this new method was invented by the company Waters Ltd in 2006 and is available to many pharmaceutical companies and researchers. This means that the method could be easily implemented and widely used for drug discovery by many research groups in a short period of time," says co-author Professor Jeremy Turnbull, University of Liverpool and Copenhagen Center for Glycomics.

The researchers plan to continue their investigations with GAGs, SIMMS2, and GAGOme (another method they developed) in hopes of improving the therapeutic effects of heparins in cancer and neurogenerative diseases like Parkinson’s.

Sources: Nature Communications, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 21, 2020
Cancer
Colorectal cancer screening kits delivered to you through the mail
JUL 21, 2020
Colorectal cancer screening kits delivered to you through the mail
New research published in the American Cancer Society’s CANCER says that improving screening rates for colorectal ...
AUG 11, 2020
Cancer
Aspirin could accelerate cancer progression in older adults
AUG 11, 2020
Aspirin could accelerate cancer progression in older adults
Alarming research published in the Journal of the National Cancer Institute points toward the association between a ...
AUG 12, 2020
Cancer
Genomic study of cervical cancers in sub-Saharan Africa
AUG 12, 2020
Genomic study of cervical cancers in sub-Saharan Africa
A first-of-its-kind study provides a comprehensive genomic study of cervical cancers in sub-Saharan Africa. Sub-Saharan ...
SEP 08, 2020
Cancer
The story of a very scary protein
SEP 08, 2020
The story of a very scary protein
New research from biochemists at the University of Alberta has identified a protein that triggers the growth of aggressi ...
SEP 10, 2020
Cancer
Pancreatic cancer patients see hope in this newly developed drug
SEP 10, 2020
Pancreatic cancer patients see hope in this newly developed drug
A new drug developed by researchers at the University of Sheffield hopes to improve life expectancy and quality of life ...
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
Loading Comments...